Junshi Biosciences Expands Roconkibart Through Fosun Alliance
Shanghai, China, July 1, 2026 Junshi Biosciences has entered into a landmark licensing collaboration with Fosun Wanbang Pharma Group,...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Shanghai, China, July 1, 2026 Junshi Biosciences has entered into a landmark licensing collaboration with Fosun Wanbang Pharma Group,...
Basel, Switzerland, July 2, 2026 Novartis has achieved a major milestone in the treatment of spinal muscular atrophy (SMA)...
